Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab in Inadequately Controlled Asthma With High Bronchodilator Reversibility
2012-003351-11Phase 2Terminated
- Sponsor
- Amgen
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Brodalumab with Placebo (2 arms). Primary endpoint: Change in ACQ composite score from baseline at week 24. Started Dec 2012; status: terminated.
02
Drugs
brodalumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2012-003351-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003351-11.